Low Ca2+ dialysate. Effects on bone metabolism in the course of paired filtration dialysis.
To evaluate the 1-year effects of PFD performed with low Ca2+ dialysate (1 mmol/l) on calcium metabolism and on bone disease, the authors studied in eight patients who were previously treated with PFD performed with standard Ca2+ dialysate (1.75 mmol/l). On samples from these subjects, the following were evaluated: 1) serum Ca2+ and PO4 levels, 2) serum PTH levels, 3) serum Al levels, and 4) bone morphology. All the patients were hypercalcemic, four with high serum PTH levels (high turnover bone disease, group 1) and four with low serum PTH levels (low turnover bone disease, group 2). In both groups, a decrease in serum Ca2+ and an increase in serum PTH was observed within the third month. In group 2, PTH levels reached the normal range. Because serum Ca2+ levels decreased to normal in both groups, it was possible to administer oral CaCO3 (10.5 +/- 2 g/day) to control serum PO4 and to stop Al gels. This did not induce any increase in serum Ca2+, whereas serum Al fell significantly. In group 1, to prevent a further rise in PTH, patients were treated with intravenous calcitriol (5 +/- 2 micrograms/week). This induced a reduction in the serum PTH without increasing serum Ca2+ or PO4. Within 12 months, an improvement in bone morphology was seen in both groups. It is concluded that the use of low Ca2+ dialysate corrects hypercalcemia in patients with PFD treated with high oral doses of CaCO3, and improves low turnover bone disease. The combination of low Ca2+ dialysate and intravenous calcitriol also improves high turnover bone disease.
Carozzi
S
S
Nephrology and Dialysis Unit, St. Paul's Hospital, Savona, Italy.
Nasini
M G
MG
Pietrucci
A
A
Costa
M
M
Mantero
R
R
D000328:Adult; D001851:Bone Diseases, Metabolic / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control; D001842:Bone and Bones / Q000378:metabolism*; D002118:Calcium / Q000032:analysis / Q000097:blood / Q000378:metabolism*; D005260:Female; D015312:Hemodialysis Solutions / Q000737:chemistry*; D006801:Humans; D006934:Hypercalcemia / Q000209:etiology / Q000378:metabolism / Q000628:therapy; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects / Q000379:methods*; D013997:Time Factors; D014511:Uremia / Q000378:metabolism* / Q000628:therapy*
D015312:Hemodialysis Solutions; D002118:Calcium